Merck to End Development of Two Cancer Candidates: Time to Sell?

Earlier this week, Merck (MRK) announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab. Merck was separately studying vibostolimab and favezelimab in fixed-dose combinations with its blockbuster cancer drug, Keytruda, under the KeyVibe and KEYFORM clinical development programs, respectively.Merck is discontinuing the KeyVibe-003 and KeyVibe-007 studies evaluating the fixed-dose combination of vibostolimab, an anti-TIGIT antibody and Keytruda in a non- ...